Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

Fig. 6

Erlotinib decreases alveolar macrophages and mediates a macrophage phenotypic switch indicative of an improved maturation. Quantification of (a) myeloid cell populations, (b) mean fluorescent intensity of the co-stimulatory molecule, CD86 in alveolar macrophages (AMs), (c) Irf5 and (d) Cd274 mRNA expression in AMs (E) PD-L1 mean fluorescent intensity on AMs in lungs of control (normal) and tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. (f) Quantification of myeloid cell populations in lungs of tumor bearing CCSP-rtTA; TetO-EGFRL858R treated with erlotinib or taken off doxycycline diet for 2 weeks or CCSP-rtTA; TetO-EGFRL858R + T790M mice in the absence (−) and presence (+) of erlotinib for 2 weeks. Data are obtained from three independent experiments, (n = 4–6 mice per group). Data are shown as mean ± SD and * is P < 0.05 in a student’s t-test

Back to article page